EA201590853A1 - Твердая солевая форма альфа-6-mpeg6-o-гидроксикодона в качестве опиоидных агонистов и ее применения - Google Patents

Твердая солевая форма альфа-6-mpeg6-o-гидроксикодона в качестве опиоидных агонистов и ее применения

Info

Publication number
EA201590853A1
EA201590853A1 EA201590853A EA201590853A EA201590853A1 EA 201590853 A1 EA201590853 A1 EA 201590853A1 EA 201590853 A EA201590853 A EA 201590853A EA 201590853 A EA201590853 A EA 201590853A EA 201590853 A1 EA201590853 A1 EA 201590853A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydroxycodon
mpeg6
applications
opioid agonists
salt form
Prior art date
Application number
EA201590853A
Other languages
English (en)
Other versions
EA029512B1 (ru
Inventor
Патрисия Андрес
Йогеш Датар
Рамакришна Гадираджу
Брюс Эндрю Ковальчик
Гэбриел Кристиан Каклис
Махмуд Мирмехраби
Николас Пасхалидес
Original Assignee
Нектар Терапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нектар Терапьютикс filed Critical Нектар Терапьютикс
Publication of EA201590853A1 publication Critical patent/EA201590853A1/ru
Publication of EA029512B1 publication Critical patent/EA029512B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В данном документе предусмотрены твердые формы конкретных опиодных агонистов. Способы получения твердых форм, способы применения твердых форм и фармацевтические композиции, содержащие твердые формы, также предусмотрены в данном документе.
EA201590853A 2012-10-30 2013-10-29 ТВЕРДАЯ СОЛЕВАЯ ФОРМА α-6-mPEG-O-ГИДРОКСИКОДОНА В КАЧЕСТВЕ ОПИОИДНЫХ АГОНИСТОВ И ЕЕ ПРИМЕНЕНИЯ EA029512B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720259P 2012-10-30 2012-10-30
US201361791894P 2013-03-15 2013-03-15
PCT/US2013/067273 WO2014070745A1 (en) 2012-10-30 2013-10-29 Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Publications (2)

Publication Number Publication Date
EA201590853A1 true EA201590853A1 (ru) 2015-08-31
EA029512B1 EA029512B1 (ru) 2018-04-30

Family

ID=49674367

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590853A EA029512B1 (ru) 2012-10-30 2013-10-29 ТВЕРДАЯ СОЛЕВАЯ ФОРМА α-6-mPEG-O-ГИДРОКСИКОДОНА В КАЧЕСТВЕ ОПИОИДНЫХ АГОНИСТОВ И ЕЕ ПРИМЕНЕНИЯ

Country Status (23)

Country Link
US (2) US9682988B2 (ru)
EP (2) EP3327022A1 (ru)
JP (2) JP6384964B2 (ru)
KR (1) KR20150076175A (ru)
CN (2) CN110615796A (ru)
AU (2) AU2013338098B2 (ru)
CA (1) CA2886276A1 (ru)
CY (1) CY1119871T1 (ru)
DK (1) DK2914599T3 (ru)
EA (1) EA029512B1 (ru)
ES (1) ES2651689T3 (ru)
HK (2) HK1213549A1 (ru)
HR (1) HRP20180315T1 (ru)
HU (1) HUE038161T2 (ru)
IL (1) IL238529A0 (ru)
LT (1) LT2914599T (ru)
ME (1) ME02971B (ru)
MX (1) MX367773B (ru)
PL (1) PL2914599T3 (ru)
PT (1) PT2914599T (ru)
RS (1) RS56898B1 (ru)
SI (1) SI2914599T1 (ru)
WO (1) WO2014070745A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) * 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
RS56898B1 (sr) * 2012-10-30 2018-04-30 Nektar Therapeutics Čvrsti oblici soli alfa-6-mpeg6-o-hidroksikodona kao opioidni agonisti i njihove upotrebe
CA3071261A1 (en) * 2017-07-27 2019-01-31 Inheris Biopharma, Inc. Oral tablet formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800334A (en) 1993-06-17 1998-09-01 Wilk; Peter J. Intrapericardial assist device and associated method
US6096337A (en) 1996-06-10 2000-08-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
EP1104290B1 (en) 1998-08-13 2010-03-31 Cima Labs Inc. Microemulsions as solid dosage forms for oral administration
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2002081477A1 (fr) * 2001-03-30 2002-10-17 Toray Industries, Inc. Derives morphinane 7-substitues et leur utilisation medicinale
WO2002080918A1 (fr) * 2001-04-02 2002-10-17 Toray Industries, Inc. Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire
DK1436012T3 (en) 2001-10-18 2018-01-22 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
JP2005053744A (ja) 2003-08-05 2005-03-03 Dsl Japan Co Ltd 高吸油性非晶質シリカ粒子
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
JP5586223B2 (ja) 2006-04-21 2014-09-10 ネクター セラピューティクス モルヒノンの立体選択的還元
WO2011011543A1 (en) * 2009-07-21 2011-01-27 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
AU2008226822B2 (en) * 2007-03-12 2013-08-01 Nektar Therapeutics Oligomer-opioid agonist conjugates
KR101660996B1 (ko) 2008-09-16 2016-09-28 넥타르 테라퓨틱스 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
WO2011088140A1 (en) * 2010-01-12 2011-07-21 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
EA023929B1 (ru) * 2010-09-30 2016-07-29 Астразенека Аб Кристаллический конъюгат налоксол-peg
EP2606879A1 (en) * 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
RS56898B1 (sr) * 2012-10-30 2018-04-30 Nektar Therapeutics Čvrsti oblici soli alfa-6-mpeg6-o-hidroksikodona kao opioidni agonisti i njihove upotrebe

Also Published As

Publication number Publication date
HK1213549A1 (zh) 2016-07-08
LT2914599T (lt) 2018-02-12
CY1119871T1 (el) 2018-06-27
EP2914599B1 (en) 2017-11-22
CN110615796A (zh) 2019-12-27
JP6384964B2 (ja) 2018-09-05
DK2914599T3 (en) 2017-12-18
ES2651689T3 (es) 2018-01-29
IL238529A0 (en) 2015-06-30
AU2013338098B2 (en) 2018-03-15
HRP20180315T1 (hr) 2018-03-23
SI2914599T1 (en) 2018-01-31
EA029512B1 (ru) 2018-04-30
JP2015535260A (ja) 2015-12-10
EP2914599A1 (en) 2015-09-09
PT2914599T (pt) 2018-01-08
HUE038161T2 (hu) 2018-09-28
PL2914599T3 (pl) 2018-05-30
CN104755481A (zh) 2015-07-01
EP3327022A1 (en) 2018-05-30
WO2014070745A1 (en) 2014-05-08
US9682988B2 (en) 2017-06-20
CA2886276A1 (en) 2014-05-08
ME02971B (me) 2018-07-20
US20170226119A1 (en) 2017-08-10
MX367773B (es) 2019-09-05
MX2015005510A (es) 2015-09-07
HK1248224A1 (zh) 2018-10-12
JP2018111718A (ja) 2018-07-19
AU2018201297A1 (en) 2018-03-15
RS56898B1 (sr) 2018-04-30
US20150284402A1 (en) 2015-10-08
AU2013338098A8 (en) 2015-05-21
AU2013338098A1 (en) 2015-04-09
KR20150076175A (ko) 2015-07-06

Similar Documents

Publication Publication Date Title
EA201692104A1 (ru) Ингибиторы асс и их применения
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201591748A1 (ru) Модуляторы p2x7
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201590887A1 (ru) Композиция
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201490037A1 (ru) Антагонисты trpv4

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU